Exact name of issuer as specified in the issuer's charter	Jabez Biosciences, Inc.
Address of Principal Executive Offices
Address 1	2009 Mackenzie Way, Suite 100
Address 2
City	Cranberry Twp
State/Country	PENNSYLVANIA
Mailing Zip/ Postal Code	16066
Phone	888-645-3947
Commission File Number(s)	024-12509

Summary Information

Date of qualification of the offering statement	12-20-2024
Date of commencement of the offering	12-20-2024
Amount of securities qualified to be sold in the offering	5000000
Amount of securities sold in the offering	19000
Price per security:	$ 2.0000
The portion of aggregate sales attributable to securities sold on behalf of the issuer	$ 10000000.00
The portion of aggregate sales attributable to securities sold on behalf of selling securityholders:	$ 0.00

Fees in connection with this offering and names of service providers.

Underwriters - Name of Service Provider		Underwriters - Fees	$
Sales Commissions - Name of Service Provider		Sales Commissions - Fee	$
Finders' Fees - Name of Service Provider		Finders' Fees - Fees	$
Accounting or Audit - Name of Service Provider	Astra Audit & Advisory LLC	Accounting or Audit - Fees	$ 10000.00
Legal - Name of Service Provider	Byrd Campbell, P.A.	Legal - Fees	$ 45000.00
Promoters - Name of Service Provider		Promoters - Fees	$
Blue Sky Compliance - Name of Service Provider		Blue Sky Compliance - Fees	$

CRD Number of any broker or dealer listed

Net proceeds to the issuer

$ 0.00

Clarification of responses (if necessary):

Certification

Title of each class of securities covered by this Form	Class A Common Stock
Commission File Number(s)	024-12509
Approximate number of holders of record as of the certification date	38

Signature

Pursuant to the requirements of Regulation A,

Cik	0002038185

(Name of issuer as specified in charter)

Jabez Biosciences, Inc.

certifies that it meets all of the conditions for termination of Regulation A reporting specified in Rule 257(d) and that there are no classes of securities other than those that are the subject to this Form 1-Z regarding which the issuer has Regulation A reporting obligations.

(Name of issuer as specified in charter)

Jabez Biosciences, Inc.

Has caused this certification to be signed on its behalf by the undersigned duly authorized person.

By	/s/ Tamara Jovonovich
Date	06-12-2026
Title	President

Instructions: This Part II of Form 1-Z is required by Rule 257(d) of Regulation A. An officer of the issuer or any other duly authorized person may sign, and must do so by typed signature. The name and title of the person signing the form must be typed or printed under the signature. The signatory to the filing must also manually sign a signature page or other document authenticating, acknowledging or otherwise adopting his or her signature that appears in the filing. Such document must be executed before or at the time the filing is made and must be retained by the issuer for a period of five years. Upon request, the issuer must furnish to the Commission or its staff a copy of any or all documents retained pursuant to this instruction.